Allianz SE, together with its subsidiaries, provides property-casualty insurance, life/health insurance, and asset management products and services worldwide.
FAIL · Does not pass the screen
48.92 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 16:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price48.92 USD
Fair value60.34
Ethical score30.0/100
RatingAVOID
Our investment reviews on this name
2026-10-26Read Markup48.22+1.5% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-02Read Distribution48.37+1.1% to today Accumulation gives way to Distribution after a 5% slide in 4 weeks
2026-09-06Read Accumulation50.98-4.0% to today Markup gives way to Accumulation after a 14% rise in 9 weeks
2026-07-02Read Markup44.71+9.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Allianz SE holds its Accumulation at $48.92. Consolidating, no directional conviction, held for 342 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 342 days
Price at the screen
$48.92
Valuation
13.81 trailing · 12.94 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.69
The Workings
Five Screens, Shown in Full
Does not pass. Business activity
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Financial sector: insurance
Fail
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
21.11%
Below 5%
21.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Allianz SE does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALIZY's ethical verdict changes
Today ALIZY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Conscience flag · Palestinian BDS National Committee
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on Palestinian BDS National Committee — category: Institutional Pressure / Financial. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 23% discount to our $60.34 fair value, moderate competitive moat, 12.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 23.3% margin of safety to the base estimate.
Where our models see it going: fair-value estimate $60.34, with a range of $43.64 to $71.23, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Global Insurance Giant Fails Ethical Bar
Imagine a world where every car, house, and life is insured, and Allianz SE is a titan in that world. Together with its subsidiaries, Allianz provides a vast array of insurance and asset management services on a global scale. Despite a robust revenue growth of 12% and a healthy profit margin of 10%, it stands out for all the wrong reasons in our book.
The reason we're steering clear is twofold: firstly, the ethical screen. Allianz fails on business activity grounds, a critical factor for our ethical-first approach. This is not a matter of valuation or market potential, but a hard line on ethics that we cannot compromise on. Secondly, despite the attractive forward P/E of 13.3x and a moderate moat suggesting some competitive advantage, the ethical failing overshadows any potential gains.
Risk is inherent in any investment, but here it's amplified by the ethical red flag. The market may price Allianz based on its global reach and financial metrics like a 20% ROE, but for us, the ethical dimension is a deal-breaker. The consensus strong buy from two analysts and a median target of $64 is a testament to the financial appeal, but it's the ethical failing that makes us avoid this stock.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Germany and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALIZY trades on PNK (the company is based in Germany). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Markup · changed$48.22+3.0%Entry 17
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $64.
2026-10-12Distribution$46.81-3.2%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it none, with a mean price target of $64.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it buy, with a mean price target of $64.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (1 analysts) rates it strong buy, with a mean price target of $79.
2026-08-07Markup$50.39+0.0%Entry 13
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-06Markup$50.39+4.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup$48.46+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-04Markup$48.46+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-03Markup$48.46+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-02Markup$48.46+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (2 analysts) rates it strong buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
